Viking Therapeutics, Inc. (VKTX) Cash Flow Statement
Viking Therapeutics, Inc. (VKTX) generated -$418.4M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$418.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VKTXViking Therapeutics, Inc.Follow VKTX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.7 | -11.1 | -14.8 | -18.8 | -24.8 | -21.8 | -47.6 | -48.4 | -73.4 | -87.8 | -278.7 | -418.4 | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | — | — | — | — | — | — | — | — | — | -87.8 | -278.7 | -418.4 | |
| Share repurchases | 0.0 | 0.0 | — | — | — | — | — | 6.8 | — | — | — | — | |
| Stock-based compensation | 2.6 | 1.8 | 1.5 | 2.6 | 3.7 | 5.8 | 6.1 | 8.7 | 16.8 | 29.7 | 40.8 | — |
USD millions · SEC XBRL
Viking Therapeutics, Inc. — questions
- What is Viking Therapeutics, Inc.'s operating cash flow?
- -$418.4M over the twelve months to 2026-06-30.
- How much does Viking Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Viking Therapeutics, Inc.'s free cash flow?
- -$418.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Viking Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.